Vaccination News Home Page

http://hoovnews.hoovers.com/fp.asp?layout=displaynews&doc_id=NR20020808670.2_f18a0004bfaa04ba

Home Companies & Industries IPO Central News Center Information Marketplace Hoover's Publications Log In Subscribe
Hoover's US, France, Italy, Spain, Germany Hoover's UK Hoover's France Hoover's Italy Hoover's Spain Hoover's Germany | Subscribe | About Hoover's | Advertise | Site Map | Help | Log Out
primary_nav5
Company News 
IPO News 
Market News 
Industry News 
Free Newsletters 
NewsStand 
E-Mail News Alerts 
UK News   
Business Links 

 Search   for     Advanced Search (See Sample)
Lead Finder
  Hoover's Online MembersHoover's Online Commercial Members
Print This Story | E-mail This Story  | Create E-mail News Alert
 
Back To News
Mutation risk from vaccine for meningitis

 

August 8, 2002 4:55pm

 

COLLETT Geoff
08/08/2002

 

Advertisement: Explore Within This Space

The Ministry of Health has been warned its major weapon against the meningococcal epidemic could be at risk from a mutant form of the disease developing.

 

The warning has come from a British expert in meningococcal disease, Professor Keith Cartwright, in an assessment of the ministry's $200 million strategy to develop a meningococcal vaccine.

 

Meningococcal disease, which causes meningitis and septicaemia, has been at epidemic levels in New Zealand for 11 years claiming close to 200 lives.

The meningococcal bacteria is genetically "mobile" and the strain responsible for most of the New Zealand epidemic is specific to this country, demanding a tailor-made vaccine to attack it.

In an analysis of the project in January, released to The Press under the Official Information Act this week, Professor Cartwright said it was possible some of the bacteria could survive the vaccine, then mutate to create vaccine-resistant varieties that could trigger new cases of the disease.

He said the true level of the risk was extremely difficult to assess but estimated it could be up to 30 per cent if the vaccine did not bring the epidemic to a rapid halt, and the bacteria was still around five to eight years after the vaccine was introduced.

A "more optimistic scenario" was that the vaccination project would terminate the epidemic quickly, before "escape mutants" could develop. Professor Cartwright estimated there was a 90 per cent chance that the vaccine would bring the epidemic under control within three to four years. He said that if a mutant bacteria did develop, it could be possible to reformulate the vaccine although that would add to the cost and complexity of the programme.

The ministry's meningococcal vaccine strategy project manager, Jane O'Hallahan, said her group was confident that the risk was "theoretical" and smaller than Professor Cartwright had suggested.

Copyright 2002.  All Rights Reserved.

Financial Times Information Limited - Asia Africa Intelligence Wire


Copyright © 2002 Financial Times Limited, All Rights Reserved

 



 

 

 

Vaccination News Home Page

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.